Tetraphase Pharmaceuticals, Inc.
) is working hard to develop its pipeline. We believe the
pipeline at Tetraphase must deliver to facilitate the company's
long-term growth. Currently, the company does not have any
The lead pipeline candidate at Tetraphase is eravacycline. The
candidate is being developed for many indications including
complicated urinary tract infections (cUTI) and complicated
intraabdominal infections (cIAI).
Tetraphase has revealed the design of the phase III IV/oral
study on eravacycline, for the treatment of cUTI patients. The
study is expected to be initiated by year end. The randomized,
multi-center, double-blind study will compare the safety and
efficacy of eravacycline against
Johnson & Johnson
) Levaquin (levofloxacin) in cUTI patients.
This study will be carried out in two parts. The first part
will be the lead-in portion of the study consisting 120 patients.
Tetraphase stated in its press release that after the lead-in
portion, an interim analysis will be conducted to assess the
primary efficacy, safety and tolerability endpoints for
determining the dosage to be used in the second part of the
The second part of the study will enroll 720 patients. They
will be administered the selected dosage of either eravacycline
or Levaquin. Clinical and microbiological response around seven
days following the completion of the therapy will be the primary
endpoint of this part of the phase III study.
We note that eravacycline is also being evaluated in a
separate phase III study for treating cIAI patients. Tetraphase
enrolled the first patient in this randomized, double-blind,
double-dummy, multicenter, prospective clinical study in Aug
Tetraphase intends to enrol 536 adults for the study in around
100 centers around the globe. Tetraphase will be evaluating the
efficacy, safety and pharmacokinetics of eravacycline in
Merck & Co. Inc.
) Invanz (ertapenem) in patients suffering from cIAI. We expect
investor focus to stay on the development of eravacycline.
Tetraphase presently carries a Zacks Rank #3 (Hold). Companies
that currently look well-positioned include
) with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
To read this article on Zacks.com click here.